Resverlogix (RVX) Shares Up 17.2%
Resverlogix Corp. (TSE:RVX)’s share price shot up 17.2% on Monday . The stock traded as high as C$4.00 and last traded at C$3.95. 172,674 shares were traded during mid-day trading, an increase of 221% from the average session volume of 53,830 shares. The stock had previously closed at C$3.37.
The stock has a market cap of $801.22 million and a price-to-earnings ratio of -6.87.
Resverlogix (TSE:RVX) last issued its quarterly earnings data on Friday, March 15th. The biotechnology company reported C($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.04) by C($0.05). On average, research analysts forecast that Resverlogix Corp. will post -0.269999996625 EPS for the current fiscal year.
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.